Skip to content
Heart icon (animated) heart icon (static)
Explore more Johnson & Johnson sites:
A graphic of the flag of Australia alt
A graphic of the flag of Argentina alt
A graphic of the flag of Brazil alt
A graphic of the flag of Chile alt
A graphic of the national flag of the People's Republic of China alt
A graphic of the national flag of Colombia alt
A graphic of the national flag of Ecuador alt
A graphic of the flag of Germany alt
A graphic of the national flag of India alt
A graphic of the national flag of Japan alt
A graphic of the flag of Mexico alt
A graphic of the flag of Paraguay alt
A graphic of the flag of Peru alt
A graphic of the flag of Russia alt
Switzerland
A graphic of the flag of Switzerland alt
A graphic of the national flag of Uruguay alt
A graphic of the flag of Venezuela alt
Share
Download Report

Janssen Pharmaceutical Companies of Johnson & Johnson Selected Novel Therapies - Recent Approvals/Potential Filings* (2021-2025 Key Filings, As Outlined at 2021 Pharm Business Review)

Selective Highlights as of April 19, 2022

Novel Therapies APPROVED

Oncology

CARVYKTI (Ciltacabtagene autoleucel)

Relapsed refractory Multiple Myeloma
US

RYBREVANT (amivantamab)

Non Small Cell Lung Cancer

Novel Therapies in REGISTRATION

Oncology

CARVYKTI (Ciltacabtagene autoleucel)

Relapsed refractory Multiple Myeloma
EU

teclistamab (BCMA/CD3)

Relapsed Refractory Multiple myeloma

Novel Therapies PLANNED FILINGS

Cardiovascular and Metabolism

aprocitentan

Difficult to treat hypertension

Milvexian (Factor XIa)

Prevention and Treatment of Thrombosis

RPGR AAV Gene Therapy

X-linked retinitis pigmentosa
Immunology

Oral IL-23i

Psoriasis

​nipocalimab

Warm Autoimmune Hemolytic Anemia
Infectious Diseases and Vaccines

JNJ-3989 siRNA

HBV/HDV Co-infection

RSV Adult Vaccine

RSV vaccine
Neuroscience

Aticaprant

Adjunctive treatment for major depressive disorder

seltorexant

Adjunctive treatment for major depressive disorder with insomnia symptoms
Oncology

niraparib

Metastatic castration-resistant prostate cancer (mCRPC)

talquetamab (GPRC5D/CD3)

Multiple myeloma

TAR-200 (RIS/gemcitabine)

Bladder Cancer
Pulmonary Hypertension

Macitentan 75mg

Pulmonary Arterial Hypertension
Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company’s knowledge. Johnson & Johnson assumes no obligation to update this information. BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BCMA CAR-T licensed from Legend Biotech; Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab , Talquetamab); Lazertinib licensed from Yuhan Corporation; Retinal assets (Achromatopsia: AAV-CNGA3, AAV-CNGB3) and (X-Linked Retinitis Pigmentosa: AAV-RPGR) licensed from MeiraGTx;
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue